Last reviewed · How we verify
GSK257049 Dosage 2
GSK257049 is a candidate malaria vaccine developed by GlaxoSmithKline, which has completed several Phase 2 and Phase 3 trials in infants, children, and adults. The vaccine aims to reduce the incidence of malaria disease and has shown promising safety and immunogenicity profiles.
At a glance
| Generic name | GSK257049 Dosage 2 |
|---|---|
| Also known as | RTS, S/AS01B |
| Sponsor | GlaxoSmithKline |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
- Pain
- Erythema
- Swelling
- Headache
- Fatigue
- Myalgia
- Gastrointestinal disorder
- Pyrexia
- Arthropod bite
- Upper respiratory tract infection
- Chills
- Feeling hot
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK257049 Dosage 2 CI brief — competitive landscape report
- GSK257049 Dosage 2 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI